基于深度学习模型和分子对接的阿尔茨海默病查目标和治疗药物
Ya-Hong Zhang1, Pu Zhao1, Hui-Ling Gao1
1College of Life and Health Sciences, Northeastern University, Shenyang, China.
Journal of Alzheimer's disease : JAD
|July 12, 2024
概括
这项研究使用深度学习和转录组分析确定了7种新药标和10种潜在的阿尔茨海默病 (AD) 药物. 这些发现为AD治疗提供了新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种复杂的神经退行性疾病,没有确定的治疗方法.
- 针对特定途径的药理干预是AD的经济有效的治疗策略.
- 识别新的药物标和有效药物对于推进AD治疗至关重要.
研究的目的:
- 通过分析转录基因数据来确定阿尔茨海默病 (AD) 的新疗法标和药物.
- 采用一种新的方法,将多层感知子 (MLP) 与差异基因表达和分子对接相结合.
主要方法:
- 不同基因表达分析和AD和对照脑组织的转录组数据的差异评估.
- 利用多层感知子 (MLP) 模型来确认已识别的基因与AD的关联.
- 分子对接和药物数据库选,以确定针对已识别的基因的潜在候选药物.
主要成果:
- 确定了七个差异表达的基因 (ANKRD39,CPLX1,FABP3,GABBR2,GNG3,PPM1E,WDR49) 作为潜在的AD药物标.
- 发现了几种化合物 (例如,阿巴克洛芬,YC-1) 与GABBR2和FABP3.3有很高的亲和力.
- 阿巴克洛芬和YC-1显示了激活GABAB受体的潜力,促进神经元的存活和减少AD病理标志物 (p-tau,Aβ).
结论:
- 开发了一种基于深度学习的新策略,用于识别AD治疗点和药物.
- 选择了七个关键的治疗点和十种潜在的药物,为AD治疗提供了新的见解.
- 确定的目标和药物为开发针对阿尔茨海默病的创新药物干预提供了基础.
相关概念视频
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461


